Chris DeMuth's State of the Markets May 2024

Episode Summary

Executive Summary: The episode focuses on event-driven and merger-arbitrage investing, with extended debate on Capri/Tapestry antitrust risk, the failed strategic review and activist situation at EHAB, new opportunities in ECIP-backed community bank acquisitions, and a unique IMBX merger/spin/CVR structure. The hosts emphasize judging deals by downside, regulatory deference, and how unusual structures can create mispriced opportunities.

Main Topics: Capri/Tapestry antitrust case and market pricing (Priority: 5/5): Chris argues the market definition hearing went badly for the companies and that judges often defer heavily to the government, especially in antitrust cases with little judicial experience. The discussion weighs breakup downside, deal probability, and how negative internal documents can affect both legal risk and valuation. EHAB activist situation and failed strategic review (Priority: 5/5): The hosts discuss EHAB’s post-spin underperformance, an apparently flawed sale process, and the arrival of an activist pushing for board and management change. They debate how much to trust complaints from bidders versus the possibility of management entrenchment. ECIP banks and acquisition optionality (Priority: 4/5): They examine a recent bank sale as a signal that ECIP-backed institutions can be monetized, potentially by non-ECIP buyers. Chris argues that if such deals clear regulatory hurdles, it could unlock a wave of similar transactions and reveal hidden value in these prefunded banks. Regulatory and political environment for healthcare deals (Priority: 4/5): EHAB and broader healthcare M&A are framed within a hostile regulatory backdrop, especially for UnitedHealth and other large healthcare players. The hosts think a change in administration could materially improve deal-making conditions later in the year. IMBX merger, CVR, and spin-off structure (Priority: 5/5): The closing IMBX transaction is highlighted as an unusual combination of merger, cash, non-traded CVR, and spin-off. The speakers argue that such structures are hard for many investors to size, but can be attractive if the post-spin asset follows a Biohaven-like path. Portfolio construction and sizing around unique events (Priority: 4/5): The episode repeatedly returns to the problem of sizing special situations when the expected value is attractive but the structure is hard to model or capital-constrained by mandates. The hosts stress flexible mandates and attention to downside protection over rigid rules.

Key Arguments: In antitrust deals like Capri/Tapestry, judicial deference to the government can matter more than the legal merits, making the judge’s temperament and appointment history highly relevant. Management comments calling a competitor a "disaster" may be strategically harmful in litigation because they can support the government’s narrative and worsen downside if the deal breaks. EHAB’s sale process appears flawed because likely buyers were excluded, follow-up meetings were not pursued, and timing issues may have prevented natural bidders from re-entering. Even if the EHAB process was sloppy, bidders and activists may exaggerate the misconduct; investors should discount claims from unhappy participants and look at incentives. ECIP bank value may be underappreciated if acquirers can keep the ECIP funding after buying a bank, turning these institutions into attractive takeover targets rather than permanent standalone entities. Regulators’ efforts to preserve small community banks can backfire by preventing those banks from investing in modern technology, cybersecurity, and customer experience, which may ultimately hurt the communities they are meant to protect. The IMBX structure is interesting because the cash portion is likely easy to value, but the CVR and spin-off create a situation where the market may misprice the residual upside. Flexible mandates are important because event-driven positions can require large notional exposure just to gain a modest economic stake in the true upside instrument, especially with CVRs and delayed payouts.

Data Points: Capri stock price: just above 34 - Referenced as the trading level while discussing market-implied odds for the merger outcome. Capri deal downside estimate: $25 per share - Used as a breakup downside assumption in probability math. Capri deal upside estimate: $57 per share - Used as a value if the transaction closes. Capri implied closing probability: about 31% - Derived from a $34 stock price using $57 upside and $25 downside. Capri implied closing probability with $20 downside: about 40% - Alternative probability estimate if breakup value were lower. EHAB structure: spin-off - The company is described as a spun-off healthcare services business focused on home, hospital, and hospice care. ECIP sale premium: 80% - Described in the BCB/Bake community bank sale discussion. BCBOA share sale price: $14 per share - Sale value mentioned for the ECIP bank transaction. IMBX deal cash component: $30 - The merger consideration is mostly cash, with additional CVR/spin-off value still uncertain. IMBX trading price: around 34 - Used to illustrate the value embedded in the residual CVR and spin-off. IMBX closing timing: less than 12 hours / closing today - The hosts note the transaction is essentially certain to close by the time listeners hear the episode. CVR example valuation: $10 present value - A prior example discussed to illustrate how hard it is to size delayed-contingent payouts. Biohaven spin-off reference: traded from about 5-6 to 30 in 18 months - Cited as a precedent for a spin-off creating substantial upside after separation. Number of Santan Jules Cap Intro events: 3 per year - Ad read: two in New York City and one at Fenway Park in Boston. One-on-one meetings at Santan Jules: 8 - Ad read describing the format of the roundtables.

Pivotal Quotes: "I think it went extremely well for the government, went very badly for the companies." — Chris: Assessment of the Capri/Tapestry market-definition hearing and overall antitrust posture. "This would not be the kind of question you'd be asking yourself because it's just you're going to get the $30, you're going to get the cash, but it's entirely possible that the CPR doesn't work and the spin-off trades poorly." — Chris: Discussion of IMBX and why the residual instruments are difficult to value and size. "I think there's going to be a lot more deals like this." — Chris: Comment on ECIP bank acquisitions and the possibility of a broader wave of similar transactions.

Implications: Listeners should expect continued opportunity in event-driven and special-situation names, but with heavy emphasis on regulatory risk, legal deference, and structure complexity. Hidden value may exist in spins, CVRs, and bank deals, yet sizing and patience are critical.